In addition to its core focus on HIV prevention, IAVI works with partners to address other public health needs that disproportionately affect individuals in developing countries. IAVI applies its expertise in vaccine and antibody development in disease areas where the organization can add unique value.
In September 2018, IAVI announced a clinical asset transfer agreement with Aeras, a nonprofit organization dedicated to developing tuberculosis (TB) vaccines. There is extensive overlap among individuals and communities hit hardest by TB and HIV/AIDS. TB is the single biggest killer of people living with HIV. The expertise of the legacy Aeras clinical operations team and South African network will enable IAVI to strengthen its clinical development capacity and enhance its ability to address HIV, TB, and other important global health challenges.
In May 2018, IAVI announced a partnership with the Coalition for Epidemic Preparedness Innovations to develop a vaccine candidate against Lassa fever using its expertise in working with replicating vesicular stomatitis vectors, or VSV vectors. The World Health Organization has identified Lassa fever as one of the top emerging pathogens likely to cause severe outbreaks in the near future in its Research and Development Blueprint for Action to Prevent Epidemics.